Publications by authors named "N Stefan"
Widening research horizons on metabolic dysfunction-associated steatotic liver disease and cancer.
Trends Endocrinol Metab
January 2025
Article Synopsis
- Liver fibrosis and biological sex influence the likelihood of developing hepatocellular carcinoma (HCC) and extrahepatic cancers (EHCs) in people with metabolic dysfunction-associated steatotic liver disease (MASLD).
- The differences in cancer risk based on these factors suggest the need for tailored chemoprevention and precision medicine strategies in treating MASLD.
- This understanding calls for more research to explore how these variables can inform better treatment approaches.
Objective: Progression of prediabetes to type 2 diabetes has been associated with β-cell dysfunction, whereas its remission to normoglycemia has been related to improvement of insulin sensitivity. To understand the mechanisms and identify potential biomarkers related to prediabetes trajectories, we compared the proteomics and metabolomics profile of people with prediabetes progressing to diabetes or reversing to normoglycemia within 1 year.
Research Design And Methods: The fasting plasma concentrations of 1,389 proteins and the fasting, 30-min, and 120-min post-oral glucose tolerance test (OGTT) plasma concentrations of 152 metabolites were measured in up to 134 individuals with new-onset diabetes, prediabetes, or normal glucose tolerance.
The global epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide. People with MASLD can progress to cirrhosis and hepatocellular carcinoma and are at increased risk of developing type 2 diabetes, cardiovascular disease, chronic kidney disease, and extrahepatic cancers. Most people with MASLD die from cardiac-related causes.
View Article and Find Full Text PDFBackground: The potential impact of specific food additives, common in Western diets, on the risk of developing type 2 diabetes is not well understood. This study focuses on carrageenan, a widely used food additive known to induce insulin resistance and gut inflammation in animal models, and its effects on human health.
Methods: In a randomised, double-blind, placebo-controlled, cross-over trial conducted at a university hospital metabolic study centre, 20 males (age 27.
Article Synopsis
- - Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly common condition that significantly impacts health by raising risks for liver complications, cardiometabolic issues, and gastrointestinal (GI) cancers, which are a major contributor to cancer deaths globally.
- - The review explores evidence linking MASLD to non-liver GI cancers, examining factors that may explain this increased risk and highlighting the need for tailored screening for individuals with MASLD.
- - Potential treatments like aspirin, statins, and metformin may help reduce the risk of GI cancers associated with MASLD, but more research is needed to solidify these findings.